Call 800-642-5297

Practice Areas

Prescription Testosterone

Prescription testosterone has been linked to heart attack, stroke and blood clots.

Testosterone manufacturers aggressively market directly to men age 40 and up with symptoms of low testosterone. The product comes in several forms, including gel, tablets, patches and injections. One manufacturer has coined the term, “low T,” and suggests a return to a fuller, happier sex life if its’ product is purchased. However, the labeling does not include adequate warning of the very real risks of heart attack and stroke that many medical professionals believe is needed with this product.

If you or a loved one suffered a heart attack or stroke while taking prescription testosterone, we would like to meet with you. Please contact our offices for a free evaluation.


Xarelto® is an anticoagulant (blood thinner) used to prevent the formation of blood clots thereby reducing the risk of certain types of stroke, heart attack, pulmonary embolism and deep vein thrombosis. It is advertised by its makers Bayer and Janssen Pharmaceuticals, as leading the new generation of anticoagulants. The drug was offered as a safer, easier alternative to Warfarin, which has been on the market for more than 50 years and requires daily monitoring, dosing adjustments and has dietary limitations. Some of the major selling points advertised by its makers were that, unlike warfarin Xarelto® was fixed dosing, required no routine monitoring, needed no dose adjustments for age, weight or gender and had no known dietary restrictions. Indeed, these were major selling points for the drug and combined with an aggressive ad campaign accounted for sales approaching almost $1 billion in 2014.

Xarelto® has now been implicated in reports of fatal bleeding with no known reversal agent. It is believed that the drug’s makers failed to advise doctors and patients on how to use Xarelto® in the safest way and that routine blood tests could identify patients at risk for major bleeding events relative to other treatment options. There have been thousands of adverse events reported concerning Xarelto® and more than 150 deaths associated with Xarelto® since it received FDA approval in 2011. Side effects include:

  • Uncontrollable bleeding
  • Internal Hemorrhage
  • Stroke
  • Heart Attack

We are filing lawsuits on behalf of people who were injured or died as a result of severe bleeding while taking Xarelto®. If you or a loved one were hospitalized as a result of severe bleeding while taking Xarelto® we would like to meet with you. Please contact our offices for a free evaluation.


Zofran® (ondansetron) is produced by GlaxoSmithKline and approved by the FDA in 1991 to prevent nausea and vomiting that some patients suffer when receiving chemotherapy, radiation or anesthesia. A generic version of this drug was produced in 2001. The product comes of 4 mg, 8mg tablets and in liquid form. The drug was never approved to treat morning sickness and nausea while pregnant, however there is belief that the drug was widely used by for this purpose. In 2012, GlaxoSmithKline, plead guilty and agreed to pay $3 Billion to resolve fraud allegations and failure to report safety data.1 According to the United States Justice Department Press Release, “This settlement resolved allegations that GSK promoted certain forms of Zofran, approved only for post-operative nausea, for the treatment of morning sickness in pregnant women.” It is important to note that GSK no doubt so a huge opportunity because between 1983, when Bendectin was voluntarily taken off the market by Merrel Dow and April, 2013, when it was reintroduced and approved under the name Diclegis, there was no FDA-approved drug to treat the pregnancy-related symptoms of nausea and vomiting.2

In August, 2013, researchers reported a two-fold increase in cardiovascular defects in children born to mothers who took Zofran during their first trimester of pregnancy. The study went on to find women taking Zofran during the first trimester of their pregnancy were 30% more likely to have a child with birth defects,3 including:

  • Cleft lip
  • Cleft palate
  • Heart defects
  • Musculoskeletal defects
  • Kidney defects
  • Fetal death

In June, 2012 the Food and Drug Administration issued an updated warning about a potential risk of issued an updated warning about the possible increased risk of prolongation of the QT interval, which can result in the potentially fatal arrhythmia.

If you took Zofran during your pregnancy to control nausea and vomiting and suffered an arrhythmia that required medical treatment or delivered a baby that was born with any of the above conditions, we would like to speak with you.



3 [tt_news]=221089&cHash=da03e20e36